13 March 2020
As a precautionary measure, all meetings of EMA committees and working parties will be held virtually until the end of April 2020. In addition, stakeholder events hosted by EMA which were planned to take place at the Agency’s premises in Amsterdam in March and April will either be held virtually or postponed until later in the year.
This measure aims to limit international travel and the number of visitors coming to EMA’s offices, in order to reduce the risk of an infection with the novel coronavirus for delegates, visitors and staff.
EMA has also initiated its Business Continuity Plan to provide a clear structure for the Agency’s management of the COVID-19 crisis. The Agency’s overarching goal is to ensure that the assessment and monitoring of medicines are not disrupted and that patients in Europe continue to have access to high quality, safe and effective treatments during the COVID-19 outbreak.
The European Commission’s Directorate-General for Health and Food Safety, the European Centre for Disease Prevention and Control (ECDC) and EMA will have videoconferences three times per week to share information and expertise as efficiently as possible.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
The Future of Pharmacy: How Advancements in Technology Are Transforming the Field
23 April 2024
Analysis Forecasts Up to 16.5% of Population Will Have Chronic Kidney Disease by 2032
23 April 2024
Microbial burden assessment of solid pharmaceutical products
22 April 2024
Seasonal variation of microbial contamination in pharmaceutical cleanrooms
22 April 2024